Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

18/09/2023 – AB Science today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) timetable for examination of the masitinib marketing authorization application in amyotrophic lateral sclerosis (ALS)